TY - JOUR
T1 - Outpatient treatment and clinical outcomes of bacteriuria in veterans
T2 - A retrospective cohort analysis
AU - the UTI Management Improvement Group
AU - Rovelsky, Suzette A.
AU - Vu, Michelle
AU - Barrett, Alexis K.
AU - Bukowski, Kenneth
AU - Wei, Xiangming
AU - Burk, Muriel
AU - Jones, Makoto
AU - Echevarria, Kelly
AU - Suda, Katie J.
AU - Cunningham, Francesca
AU - Madaras-Kelly, Karl J.
AU - Aylward, Andrea
AU - Carr, Nikki
AU - Curley, Sean
AU - Tu, Patrick
AU - Siv, Melanie
AU - Walton, Angelia
AU - Hong, Joseph
AU - Miller, Nicole Storm
AU - Branton, Alexander
AU - Dhanani, Muhammad
AU - Strymish, Judith
AU - Vest, Kirsten
AU - Chang, Mei
AU - Kish, Troy
AU - Bowser, Alyssa
AU - Caniff, Kaylee
AU - Beshalske, Andrea
AU - Young, Lisa
AU - Segarra-Newnham, Marisel
AU - Kuhn, Ryan
AU - Walker, Michele
AU - Buie, Kandise
AU - Rushano, Michelle
AU - Potter, Emily
AU - Shafiq, Ashafq
AU - Juan, Ashley
AU - Davis, Kelly
AU - Matano, Jacob
AU - Bennett, Jessica
AU - Guidry, Tommie Jo
AU - LeBaron, Brian
AU - Hamilton, Angelia
AU - Foral, Pamela
AU - Grammar, Ashleigh
AU - Mitchell-Bueso, Andrew
AU - Baxter, Kelly
AU - Specht, Whitney
AU - Phabmixay, Jenny
AU - Marceau, Anna
N1 - Funding Information:
This work was supported by the resources of the Department of Veterans’ Affairs. As a quality improvement project, no grant funding was used to support this work.
Publisher Copyright:
© Veterans Health Administration, 2022.
PY - 2022/10/12
Y1 - 2022/10/12
N2 - Objective: To conduct a contemporary detailed assessment of outpatient antibiotic prescribing and outcomes for positive urine cultures in a mixed-sex cohort. Design: Multicenter retrospective cohort review. Setting: The study was conducted using data from 31 Veterans’ Affairs medical centers. Patients: Outpatient adults with positive urine cultures. Methods: From 2016 to 2019, data were extracted through a nationwide database and manual chart review. Positive urine cultures were reviewed at the chart, clinician, and aggregate levels. Cases were classified as cystitis, pyelonephritis, or asymptomatic bacteriuria (ASB) based upon documented signs and symptoms. Preferred therapy definitions were applied for subdiagnoses: ASB (no antibiotics), cystitis (trimethoprim-sulfamethoxazole, nitrofurantoin, β-lactams), and pyelonephritis (trimethoprim-sulfamethoxazole, fluoroquinolone). Outcomes included 30-day clinical failure or hospitalization. Odds ratios for outcomes between treatments were estimated using logistic regression. Results: Of 3,255 cases reviewed, ASB was identified in 1,628 cases (50%), cystitis was identified in 1,156 cases (36%), and pyelonephritis was identified in 471 cases (15%). Of all 2,831 cases, 1,298 (46%) received preferred therapy selection and duration for cases where it could be defined. The most common antibiotic class prescribed was a fluoroquinolone (34%). Patients prescribed preferred therapy had lower odds of clinical failure: preferred (8%) versus nonpreferred (10%) (unadjusted OR, 0.74; 95% confidence interval [CI], 0.58–0.95; P = .018). They also had lower odds of 30-day hospitalization: preferred therapy (3%) versus nonpreferred therapy (5%) (unadjusted OR, 0.55; 95% CI, 0.37–0.81; P = .002). Odds of clinical treatment failure or hospitalization was higher for β-lactams relative to ciprofloxacin (unadjusted OR, 1.89; 95% CI, 1.23–2.90; P = .002). Conclusions: Clinicians prescribed preferred therapy 46% of the time. Those prescribed preferred therapy had lower odds of clinical failure and of being hospitalized.
AB - Objective: To conduct a contemporary detailed assessment of outpatient antibiotic prescribing and outcomes for positive urine cultures in a mixed-sex cohort. Design: Multicenter retrospective cohort review. Setting: The study was conducted using data from 31 Veterans’ Affairs medical centers. Patients: Outpatient adults with positive urine cultures. Methods: From 2016 to 2019, data were extracted through a nationwide database and manual chart review. Positive urine cultures were reviewed at the chart, clinician, and aggregate levels. Cases were classified as cystitis, pyelonephritis, or asymptomatic bacteriuria (ASB) based upon documented signs and symptoms. Preferred therapy definitions were applied for subdiagnoses: ASB (no antibiotics), cystitis (trimethoprim-sulfamethoxazole, nitrofurantoin, β-lactams), and pyelonephritis (trimethoprim-sulfamethoxazole, fluoroquinolone). Outcomes included 30-day clinical failure or hospitalization. Odds ratios for outcomes between treatments were estimated using logistic regression. Results: Of 3,255 cases reviewed, ASB was identified in 1,628 cases (50%), cystitis was identified in 1,156 cases (36%), and pyelonephritis was identified in 471 cases (15%). Of all 2,831 cases, 1,298 (46%) received preferred therapy selection and duration for cases where it could be defined. The most common antibiotic class prescribed was a fluoroquinolone (34%). Patients prescribed preferred therapy had lower odds of clinical failure: preferred (8%) versus nonpreferred (10%) (unadjusted OR, 0.74; 95% confidence interval [CI], 0.58–0.95; P = .018). They also had lower odds of 30-day hospitalization: preferred therapy (3%) versus nonpreferred therapy (5%) (unadjusted OR, 0.55; 95% CI, 0.37–0.81; P = .002). Odds of clinical treatment failure or hospitalization was higher for β-lactams relative to ciprofloxacin (unadjusted OR, 1.89; 95% CI, 1.23–2.90; P = .002). Conclusions: Clinicians prescribed preferred therapy 46% of the time. Those prescribed preferred therapy had lower odds of clinical failure and of being hospitalized.
UR - http://www.scopus.com/inward/record.url?scp=85141201343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141201343&partnerID=8YFLogxK
U2 - 10.1017/ash.2022.285
DO - 10.1017/ash.2022.285
M3 - Article
C2 - 36483437
AN - SCOPUS:85141201343
SN - 2732-494X
VL - 2
JO - Antimicrobial Stewardship and Healthcare Epidemiology
JF - Antimicrobial Stewardship and Healthcare Epidemiology
IS - 1
M1 - e168
ER -